UTHR (United Therapeutics) Short Interest


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $543.39
GF Value $386.36
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

UTHR vs VTRS, NBIX, ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Short Interest falls into.


UTHR
88GF Score
United Therapeutics Corp UTHR
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $543.39 is trading 40.6% above its estimated GF Value™ of $386.36. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Short Interest:
  • GF Value™: $386.36 vs. price of $543.39 (40.6% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$543.39
Price
$386.36
GF Value